Asymchem

Benefiting from China's launch of a new round of drug procurement and a sentiment boost in the CXO sector, Asymchem surged 11.5% today after a low open, hitting an intraday high of HKD 119.5 in the afternoon session before closing at HKD 118.7. News-wise, the company unveiled its fully integrated TIDES commercial supply matrix, with Goldman Sachs, BOCOM International, and CMBC International reaffirming Buy ratings, while brokerages highlighted the CDMO industry's resilience. Financially, Q1 revenue rose 23.8% YoY to HKD 2.04 billion, though net profit edged down 1.4% YoY; net profit margin modestly improved to 16.9% from 16.3% in Q4. The stock is now just 4.6% below its 52-week high of HKD 124.4, with a YTD gain of 61.3%, and trades well above MA20 (HKD 98.9) and MA60 (HKD 98.5), indicating elevated valuation. However, today's volume of 771,840 shares was lower than the prior session, suggesting limited chase momentum.